Overview
The study aimed to compare the efficacy and safety of dual and quadruple regimens with different durations (7-day, 10-day, 14-day) for the eradication of Helicobacter pylori. Subjects were randomized to receive the intervention and were reviewed by 13C-urea breath test after 6 weeks. The eradication rates, adverse reaction rates and patient adherence were calculated.
Eligibility
Inclusion Criteria:
- Patients aged 18-70 years old
- Patients with H.pylori infection (13C/14C-urea breath test)
- Patients without previous treatment for H. pylori eradication
Exclusion Criteria:
- Patients with serious underlying diseases, such as liver insufficiency (Aspartate aminotransferase or alanine aminotransferase greater than the normal value), renal insufficiency (Cr≥2.0mg/dL or glomerular filtration rate <50 ml/min), immunosuppression, malignant tumors, Coronary heart disease or coronary artery stenosis ≥75%
- Patients with active gastrointestinal bleeding
- Patients with a history of upper gastrointestinal surgery
- Patients allergic to treatment drugs
- Patients with medication history of bismuth, antibiotics within 4 weeks, or proton pump inhibitor within 2 weeks
- Patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial
- Patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse
- Patients who are unwilling or incapable to provide informed consents